about
Progress in treatment of ANCA-associated vasculitisCyclophosphamide for connective tissue disease-associated interstitial lung diseaseIntravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosisIntravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosisIntravenous immunoglobulin for Wegener's granulomatosisAcquired pure red cell aplasia: updated review of treatmentNeurology of the vasculitides and connective tissue diseasesAutoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for preventionClinical review: Vasculitis on the intensive care unit--part 1: diagnosisWegener's granulomatosis: current and upcoming therapiesProteinase-3 as the major autoantigen of c-ANCA is strongly expressed in lung tissue of patients with Wegener's granulomatosis.Clinical review: Vasculitis on the intensive care unit -- part 2: treatment and prognosisThe Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western CountriesGranulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestationsGranulomatose avec polyangéite du sujet âgé: à propos de deux cas et revue de la littératureEpidemiology of vasculitides: differences between Japan, Europe and North AmericaPanhypopituitarism due to Wegener's granulomatosisNovel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodiesPulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literatureCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)The clinical relevance of ANCA in vasculitisPulmonary vasculitisRare diseases.3: Wegener's granulomatosisRare diseases bullet 11: Churg-Strauss syndromeThe pulmonary physician in critical care * Illustrative case 3: Pulmonary vasculitisInfectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literatureAssessment of disease activity in systemic vasculitisAnti-TNF-alpha therapy and systemic vasculitis.Bartonella Endocarditis and Pauci-Immune Glomerulonephritis: A Case Report and Review of the LiteratureChildhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysisUpdates in ANCA-associated vasculitisCorticosteroids in acute respiratory failureAirway reconstruction in Wegener's granulomatosis-associated laryngotracheal stenosisClassification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosisPathogenesis of ANCA-associated vasculitisThe immunopathology of ANCA-associated vasculitisConditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitidesTherapeutic plasma exchange and renal related vasculitis: therapeutic apheresis academy 2010.Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
P2860
Q21195258-05BAB8C0-8155-4F69-9B81-6F682DCDC33CQ24201486-0143077B-3C72-4F17-85B7-625C59F67E10Q24201647-57E91206-6C10-4469-A56C-1A50323DEC75Q24240077-97B16D1B-ACE6-4E0F-A110-7DD928BC8580Q24243687-DF40A79B-CB2A-4C8E-B6BD-CAF94E783FA9Q24652253-56F02C38-F5D3-4A67-ABB4-57D63B9CB0E2Q24679901-D0FD770C-B80F-4C62-8C6F-8D5A71C89763Q24791788-21BB72DF-4FFE-409F-BCA5-BEC03A1D0607Q24802072-06EFD5DE-F9DC-4917-9C77-E2E7CCA1167BQ24804964-12A5F7CE-8B97-412B-B847-614E085AAA83Q24807322-E62281C1-AA43-4DA7-B70F-6CE12C3330B0Q24811911-81AAF607-A69A-4D44-A726-BFA21B2D5585Q26740451-5043D335-990A-4257-B9EC-20BE451A470CQ26748200-8FDB67BB-C8C6-47A0-BC9D-BD82BB9E9470Q26801585-DA3DF3ED-588D-40BE-A965-E976E0478519Q26851162-03FE1F32-ED06-420D-8C0A-5ECCF27211DDQ26861602-B9B30ADE-204B-4D26-A917-AED14E45E7F0Q27000411-1DCB41DE-A8F7-4921-A55C-64B25DA5C727Q27008053-7C82CFA3-9FB0-480B-98D1-C76C00440A13Q27025692-1DD6FAD0-49F9-46CF-84FF-1F6515E3A249Q27473557-1A266F18-1314-43F3-9252-85771458CDA5Q27477901-8B900F76-739B-4998-AEBD-7ADBBF33F516Q27477902-21E95BE7-9FCE-4200-8B27-A4F4F26A32C8Q27477903-9238E696-7936-47BF-A19C-4478C9CC9CEEQ27477909-4EA8FA57-E45A-4A1F-9615-1B7CB9642AE6Q27477927-95E2C71C-B2F9-4FBA-8E4F-7557D996E47AQ27485913-0A03B2CE-8C34-4C19-A7E1-51664993E118Q27687590-A1C3AEF9-376B-4F47-841C-F727B111AD39Q28067381-29A3C87D-CFD7-44DE-BF38-28FE47E483CBQ28069646-149E1B0F-2A29-4688-9235-ADA8F807D0FFQ28069897-8A35FDB3-5CFA-4FBC-82B2-83CD14F24BD6Q28145486-09823C8B-983A-46E4-A571-829EC59DEA56Q28253747-F6292132-8695-4492-B51B-B1085DFC8C3BQ28389271-69C502F1-B445-4C3D-8051-3BEE2AC23C77Q28390438-F010104B-0B70-4A7A-B0F6-0AAC01EB6A30Q28391531-945C1282-62F0-4E04-8E29-539713A71E87Q28393792-26156C1A-EAB5-4CA8-89B3-F6224B699B6AQ30454083-71FBEF9A-E9D0-4251-A572-7B13FBAC0F71Q30696868-97A4165D-1FAC-404E-A5CA-9F9B14F1AAA0Q30849537-05F2493E-37FF-482D-B7BC-B630C0ADD922
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Wegener granulomatosis: an analysis of 158 patients.
@en
Wegener granulomatosis: an analysis of 158 patients.
@nl
type
label
Wegener granulomatosis: an analysis of 158 patients.
@en
Wegener granulomatosis: an analysis of 158 patients.
@nl
prefLabel
Wegener granulomatosis: an analysis of 158 patients.
@en
Wegener granulomatosis: an analysis of 158 patients.
@nl
P2093
P1476
Wegener granulomatosis: an analysis of 158 patients.
@en
P2093
Hallahan CW
Hoffman GS
Leavitt RY
Lebovics RS
P304
P356
10.7326/0003-4819-116-6-488
P407
P577
1992-03-01T00:00:00Z